TY - JOUR
T1 - The Wearable Activity Technology And Action-Planning trial in Cancer survivors
T2 - physical activity maintenance post-intervention
AU - Hardcastle, Sarah J.
AU - Maxwell-Smith, Chloé
AU - Hince, Dana
AU - Bulsara, Max K.
AU - Boyle, Terry
AU - Tan, Patrick
AU - Levitt, Michael
AU - Salama, Paul
AU - Mohan, Ganendra Raj Kader Ali
AU - Salfinger, Stuart
AU - Makin, Gregory
AU - Tan, Jason
AU - Platell, Cameron
AU - Cohen, Paul A.
PY - 2021/9
Y1 - 2021/9
N2 - Objectives The study objective was to assess whether moderate-to-vigorous intensity physical activity (MVPA) change in cancer survivors (n = 68, mean age = 64 years) was maintained 12-weeks following the Wearable Activity Technology and Action Planning (WATAAP) intervention. Secondary aims were to assess the effects of the intervention on blood pressure (BP) and body mass index (BMI), and to explore group differences between baseline and 24-weeks. Design Randomized controlled trial. Methods MVPA and sedentary behaviour were assessed using an accelerometer at baseline, the end of the intervention (12-weeks), and at 24-weeks. Generalised linear mixed models with random effects were used to examine between-group and within-group changes in MVPA, sedentary behaviour, BP and BMI. Results MVPA was significantly higher in the intervention group compared with the control group at 24-weeks following adjustment for known confounders (141.4 min/wk. (95% CI = 9.1 to 273.8), p = 0.036). At 24-weeks participants in the intervention group had maintained their increased levels of MVPA (change from 12-weeks = 8.8 min/wk.; 95% CI = −43 to 61; p = 0.74). The reduction in MVPA in the control group over the first 12-weeks was also maintained at 24-weeks (5.4 min/wk.; 95% CI = −3.6 to 4.6; p = 0.80). Secondary outcomes did not differ between groups at 24-weeks. Conclusions Our results suggest distance-based interventions using wearable technology produce increases in MVPA that endure at least 12-weeks after the intervention is completed. Australia New Zealand Clinical Trials Registry identifier: 2617000131358. WHO UTN: U1111–1191-6268.
AB - Objectives The study objective was to assess whether moderate-to-vigorous intensity physical activity (MVPA) change in cancer survivors (n = 68, mean age = 64 years) was maintained 12-weeks following the Wearable Activity Technology and Action Planning (WATAAP) intervention. Secondary aims were to assess the effects of the intervention on blood pressure (BP) and body mass index (BMI), and to explore group differences between baseline and 24-weeks. Design Randomized controlled trial. Methods MVPA and sedentary behaviour were assessed using an accelerometer at baseline, the end of the intervention (12-weeks), and at 24-weeks. Generalised linear mixed models with random effects were used to examine between-group and within-group changes in MVPA, sedentary behaviour, BP and BMI. Results MVPA was significantly higher in the intervention group compared with the control group at 24-weeks following adjustment for known confounders (141.4 min/wk. (95% CI = 9.1 to 273.8), p = 0.036). At 24-weeks participants in the intervention group had maintained their increased levels of MVPA (change from 12-weeks = 8.8 min/wk.; 95% CI = −43 to 61; p = 0.74). The reduction in MVPA in the control group over the first 12-weeks was also maintained at 24-weeks (5.4 min/wk.; 95% CI = −3.6 to 4.6; p = 0.80). Secondary outcomes did not differ between groups at 24-weeks. Conclusions Our results suggest distance-based interventions using wearable technology produce increases in MVPA that endure at least 12-weeks after the intervention is completed. Australia New Zealand Clinical Trials Registry identifier: 2617000131358. WHO UTN: U1111–1191-6268.
KW - Exercise
KW - Oncology
KW - Behaviour change
KW - Intervention
KW - Wearable activity technology
U2 - 10.1016/j.jsams.2021.04.004
DO - 10.1016/j.jsams.2021.04.004
M3 - Article
C2 - 34016536
SN - 1440-2440
VL - 24
SP - 902
EP - 907
JO - Journal of Science and Medicine in Sport
JF - Journal of Science and Medicine in Sport
IS - 9
ER -